Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

A Big Year In Biotech Was A Windfall For Top IPO Lawyers Laser-Focused On The Space (Business Insider)

Related Content

A Look Ahead in Life Sciences: What We Are Tracking in the Fourth Quarter of 2024 and Beyond

FTC Escalates Battle Against PBMs With Complaint on Insulin Pricing

Recent Biosimilar Approvals By the FDA

Preliminary Injunction Denied Against Amgen in Aflibercept BPCIA Litigation

BIOSECURE Act Timeline

Colorado's Neural Privacy Law Is a Game-Changer for Tech

Eli Lilly Files Suit Challenging the FDA’s Drug Classification of Retatrutide

Celltrion Wins Brazilian Federal Tender for Trastuzumab for Fifth Consecutive Year

Goodwin Advises Curon Biopharmaceutical in Acquisition of CN201 by Merck for $700 Million Upfront Plus up to $600 Million Milestones

The Legal 500 UK 2025 Recognizes 26 Practices and 39 Lawyers Across Goodwin’s UK Platform

Goodwin Names 35 New Partners

Goodwin Advises Prime Medicine in Collaboration with Bristol Myers Squibb to Develop Multiple Ex Vivo T-Cell Therapies, with $110M Upfront and Up to $3.5B in Milestones

Goodwin Advises Generate:Biomedicines on $1B-Plus Deal with Novartis to Develop Protein Therapeutics

Goodwin Advises Collaboration Between Korro Bio and Novo Nordisk to Develop Two Therapeutic Candidates

SOLASTA Bio Completes $14m Series A

Goodwin Advises Bicara’s $362 Million Upsized Initial Public Offering

Life Sciences

Technology

Capital Markets